Charles Oshaughnessy, MD
Interventional Cardiology · Elyria, OHNPI 1831178003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,550 of the $13,783 with a category attached, or 76.5%. AstraZeneca accounts for 79.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $6,335 and has fallen 96.7% since, to $209 in 2025.
Across 80 payments — averaging $172.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Medtronic$2K
- Abbott$357
- Novartis$242
- Abiomed$187
- E.r. Squibb & Sons, L.L.C.$184
- plus $305 from 10 others
Across 45 payments — averaging $575.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$18K
- Medtronic$8K
What the payments were for
- Speaking & faculty fees$10,55077%
- Travel & lodging$9287%
- Food & beverage$2,30517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $10,949 |
| Medtronic(2 entities) | 16 | $1,558 |
| Abbott | 6 | $357 |
| Novartis | 13 | $242 |
| Abiomed | 3 | $187 |
| E.r. Squibb & Sons, L.L.C. | 10 | $184 |
| Atricure, Inc. | 5 | $94 |
| Heartflow, Inc. | 1 | $57 |
| Amgen | 3 | $53 |
| Novo Nordisk | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Surmodics, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Bard Peripheral Vascular, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$10,791
- Resolute$789
- Xience V coronary stent system$150
- ONYX FRONTIER$133
- Impella$126
- CoreValve Evolut$122
How this compares
$13,783 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 541 | $663,885 |
| EntrestoSacubitril/Valsartan | 197 | $258,977 |
| XareltoRivaroxaban | 134 | $148,703 |
| Repatha SureclickEvolocumab | 109 | $123,430 |
| JardianceEmpagliflozin | 41 | $60,846 |
| BrilintaTicagrelor | 35 | $28,952 |
| Atorvastatin Calcium | 1,716 | $19,120 |
| Ranolazine ErRanolazine | 152 | $17,014 |
| ClopidogrelClopidogrel Bisulfate | 1,025 | $12,507 |
| Metoprolol Succinate | 750 | $10,671 |
| Potassium Chloride | 326 | $8,398 |
| Nitroglycerin | 549 | $7,714 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 371 | $6,163 |
| Metoprolol Tartrate | 941 | $5,658 |
| Losartan Potassium | 570 | $5,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $663,885541 claims |
| NovartisEntresto | $242 | $258,977197 claims |
| Boehringer IngelheimJardiance | $13 | $60,84641 claims |
| AstraZenecaBrilinta | $10,949 | $28,95235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Elyria
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.